Takeda Pharmaceutical Revenue 2007-2018 | TAK

Takeda Pharmaceutical annual/quarterly revenue history and growth rate from 2007 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Takeda Pharmaceutical revenue for the quarter ending December 31, 2018 was $4.445B, a 21.45% increase year-over-year.
  • Takeda Pharmaceutical revenue for the twelve months ending December 31, 2018 was $16.654B, a 7.01% increase year-over-year.
  • Takeda Pharmaceutical annual revenue for 2018 was $15.935B, a 1.08% decline from 2017.
  • Takeda Pharmaceutical annual revenue for 2017 was $16.108B, a 7.38% increase from 2016.
  • Takeda Pharmaceutical annual revenue for 2016 was $15.001B, a 7.27% decline from 2015.
Takeda Pharmaceutical Annual Revenue
(Millions of US $)
2018 $15,935
2017 $16,108
2016 $15,001
2015 $16,178
2014 $16,917
2013 $18,843
2012 $19,163
2011 $17,101
2010 $15,763
2009 $15,697
2008 $13,748
2007 $11,061
2006 $10,361
Takeda Pharmaceutical Quarterly Revenue
(Millions of US $)
Q3 2018 $4,445
Q1 2018 $4,138
Q1 2017 $4,034
Q1 2016 $4,036
Q1 2015 $3,660
Q4 2015 $3,673
Q3 2014 $4,153
Q2 2014 $4,076
Q1 2014 $4,017
Q4 2014 $3,982
Q3 2013 $4,528
Q2 2013 $4,222
Q1 2013 $4,171
Q4 2013 $3,722
Q3 2012 $4,959
Q2 2012 $4,936
Q1 2012 $5,089
Q4 2012 $4,816
Q3 2011 $5,484
Q2 2011 $4,454
Q4 2011 $4,113
Q4 2010 $3,728
Q2 2009 $2
Q4 2009 $3,594
Q4 2008 $2,839
Q4 2007 $2,525
Q4 2006 $2,371
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $33.622B $15.988B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $47.705B 31.73
Grifols (GRFS) Spain $13.132B 15.92
Ionis Pharmaceuticals (IONS) United States $11.141B 34.55
Neurocrine Biosciences (NBIX) United States $8.158B 528.41
Jazz Pharmaceuticals (JAZZ) Ireland $7.761B 11.11
Sage Therapeutics (SAGE) United States $7.440B 0.00
Tilray (TLRY) United States $6.545B 0.00
Catalent (CTLT) United States $6.280B 26.29
Nektar Therapeutics (NKTR) United States $5.829B 9.30
United Therapeutics (UTHR) United States $5.377B 9.14
FibroGen (FGEN) United States $4.759B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.340B 23.06
Taro Pharmaceutical Industries (TARO) Israel $4.251B 13.68
PTC Therapeutics (PTCT) United States $2.297B 0.00
Zogenix (ZGNX) United States $2.294B 0.00
Portola Pharmaceuticals (PTLA) United States $2.247B 0.00
Aerie Pharmaceuticals (AERI) United States $2.239B 0.00
Madrigal Pharmaceuticals (MDGL) United States $2.213B 0.00
Ironwood Pharmaceuticals (IRWD) United States $2.182B 0.00
USANA Health Sciences (USNA) United States $2.061B 17.30
Endo (ENDP) Ireland $1.966B 3.03
Enanta Pharmaceuticals (ENTA) United States $1.938B 24.13
Heron Therapeutics (HRTX) United States $1.926B 0.00
Xencor (XNCR) United States $1.807B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.797B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.639B 141.96
Theravance Biopharma (TBPH) Cayman Islands $1.374B 0.00
Corcept Therapeutics (CORT) United States $1.357B 19.72
TherapeuticsMD (TXMD) United States $1.312B 0.00
Esperion Therapeutics (ESPR) United States $1.186B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.134B 0.00
Tricida (TCDA) United States $1.069B 0.00
Radius Health (RDUS) United States $0.884B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.870B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.617B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.598B 0.00
Dermira (DERM) United States $0.577B 0.00
Collegium Pharmaceutical (COLL) United States $0.567B 0.00
GlycoMimetics (GLYC) United States $0.566B 0.00
Odonate Therapeutics (ODT) United States $0.565B 0.00
ArQule (ARQL) United States $0.560B 0.00
Forty Seven (FTSV) United States $0.551B 0.00
ChemoCentryx (CCXI) United States $0.531B 0.00
Akebia Therapeutics (AKBA) United States $0.496B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.495B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.493B 29.09
Siga Technologies (SIGA) United States $0.485B 0.00
KalVista Pharmaceuticals (KALV) United States $0.484B 0.00
Flexion Therapeutics (FLXN) United States $0.476B 0.00
Translate Bio (TBIO) United States $0.448B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.443B 0.00
TCR2 THERAPTCS (TCRR) United States $0.439B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.427B 0.00
Concert Pharmaceuticals (CNCE) United States $0.413B 0.00
OptiNose (OPTN) United States $0.391B 0.00
ImmunoGen (IMGN) United States $0.384B 0.00
Aptorum Group (APM) China $0.380B 0.00
Karyopharm Therapeutics (KPTI) United States $0.354B 0.00
Minerva Neurosciences (NERV) United States $0.324B 0.00
CASI Pharmaceuticals (CASI) United States $0.318B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.316B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.310B 11.50
Lannett Co Inc (LCI) United States $0.302B 2.81
Majesco Entertainment (PTE) United States $0.287B 0.00
Mast Therapeutics (SVRA) United States $0.284B 0.00
Immune Design (IMDZ) United States $0.282B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.278B 0.00
Xeris Pharmaceuticals (XERS) United States $0.271B 0.00
Dova Pharmaceuticals (DOVA) United States $0.264B 0.00
Affimed (AFMD) Germany $0.261B 0.00
HARPOON THERAPT (HARP) United States $0.260B 0.00
Aclaris Therapeutics (ACRS) United States $0.259B 0.00
Calithera Biosciences (CALA) United States $0.258B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.256B 0.00
ElectroCore (ECOR) United States $0.254B 0.00
Opexa Therapeutics (ACER) United States $0.237B 0.00
Tyme Technologies (TYME) United States $0.234B 0.00
Galectin Therapeutics (GALT) United States $0.222B 0.00
MEI Pharma (MEIP) United States $0.220B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.216B 0.00
Jounce Therapeutics (JNCE) United States $0.215B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.214B 0.00
Recro Pharma (REPH) United States $0.211B 0.00
Molecular Templates (MTEM) United States $0.211B 0.00
Aldeyra Therapeutics (ALDX) United States $0.208B 0.00
Ardelyx (ARDX) United States $0.205B 0.00
IMV INC (IMV) Canada $0.202B 0.00
Rafael Holdings (RFL) United States $0.195B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.192B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.191B 0.00
Redhill Biopharma (RDHL) Israel $0.188B 0.00
Taiwan Liposome, Unsponsored ADR (TLC) Taiwan $0.188B 0.00
Aratana Therapeutics (PETX) United States $0.188B 0.00
Ocular Therapeutix (OCUL) United States $0.178B 0.00
Nature's Sunshine Products (NATR) United States $0.176B 182.40
Aquestive Therapeutics (AQST) United States $0.174B 0.00
Neos Therapeutics (NEOS) United States $0.166B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.164B 0.00
Neon Therapeutics (NTGN) United States $0.156B 0.00
AgeX Therapeutics (AGE) United States $0.150B 0.00
ProNAi Therapeutics (SRRA) Canada $0.142B 0.00
MediWound (MDWD) Israel $0.140B 0.00
China SXT Pharmaceuticals (SXTC) China $0.138B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.137B 0.00
Cardiome Pharma (CORV) Canada $0.121B 0.00
Champions Oncology (CSBR) United States $0.121B 0.00
DURECT (DRRX) United States $0.119B 0.00
Zafgen (ZFGN) United States $0.112B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.111B 0.00
Adherex Technologies (FENC) United States $0.107B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.107B 0.00
Iterum Therapeutics (ITRM) Ireland $0.106B 0.00
Infinity Pharmaceuticals (INFI) United States $0.098B 0.00
Nivalis Therapeutics (ALPN) United States $0.094B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.091B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.091B 0.00
Otonomy (OTIC) United States $0.089B 0.00
Avenue Therapeutics (ATXI) United States $0.088B 0.00
Natural Alternatives (NAII) United States $0.084B 8.24
Genocea Biosciences (GNCA) United States $0.081B 0.00
SCYNEXIS (SCYX) United States $0.079B 0.00
India Globalization Capital (IGC) United States $0.078B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.070B 0.00
Ampio Pharmaceuticals (AMPE) United States $0.067B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.065B 0.00
Actinium Pharmaceuticals (ATNM) United States $0.061B 0.00
Forward Pharma (FWP) Denmark $0.059B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.058B 0.00
CTI BioPharma (CTIC) United States $0.057B 0.00
KemPharm (KMPH) United States $0.054B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.054B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.052B 0.00
Lipocine (LPCN) United States $0.052B 0.00
Capnia (SLNO) United States $0.050B 0.00
BioLineRx (BLRX) Israel $0.049B 0.00
Melinta Therapeutics (MLNT) United States $0.048B 0.00
Bio-Path Holdings (BPTH) United States $0.046B 0.00
Mannatechorporated (MTEX) United States $0.044B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.041B 0.00
NOVAN INC (NOVN) United States $0.037B 0.00
ProPhase Labs (PRPH) United States $0.037B 0.00
ContraFect (CFRX) United States $0.037B 0.00
HANCOCK JAFFE (HJLI) United States $0.035B 0.00
Achaogen (AKAO) United States $0.035B 0.00
Heat Biologics (HTBX) United States $0.030B 0.00
PharmAthene (ALT) United States $0.027B 0.00
Can-Fite Biopharma (CANF) Israel $0.027B 0.00
Citius Pharmaceuticals (CTXR) United States $0.026B 0.00
Shineco (TYHT) China $0.026B 4.42
Summit Therapeutics (SMMT) United Kingdom $0.026B 0.00
Onconova Therapeutics (ONTX) United States $0.026B 0.00
IsoRay (ISR) United States $0.025B 0.00
Biomerica (BMRA) United States $0.025B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.023B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.022B 0.00
ESSA Pharma (EPIX) Canada $0.021B 0.00
Jaguar Animal Health (JAGX) United States $0.021B 0.00
Pain Therapeutics (PTIE) United States $0.021B 0.00
NanoViricides (NNVC) United States $0.021B 0.00
Cyanotech (CYAN) United States $0.020B 0.00
Achieve Life Sciences (ACHV) United States $0.020B 0.00
Xenetic Biosciences (XBIO) United States $0.018B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.018B 0.00
VAXART, INC (VXRT) United States $0.018B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.018B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.015B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.013B 0.00
PRECISION THERAPEUTICS INC (AIPT) United States $0.012B 0.00
Regulus Therapeutics (RGLS) United States $0.012B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.012B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.012B 0.00
Midatech Pharma (MTP) United Kingdom $0.011B 0.00
Trillium Therapeutics (TRIL) Canada $0.010B 0.00
RXi Pharmaceuticals (PHIO) United States $0.008B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.007B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.006B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.000B 0.00
Bio Blast Pharma (ORPN) Israel $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00